

23

Please amend the application as follows:

In the Claims

Please cancel Claims 8-12. Please amend Claims 1-7 and 13-15, and add new Claims 16-22. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - iii).

---

- A<sup>1</sup>
1. (Amended) A CD4-specific chimeric immunoglobulin or chimeric antigen binding fragment thereof, said immunoglobulin or fragment having the epitopic specificity of monoclonal antibody M-T412 and comprising an antigen binding region of non-human origin and a constant region of human origin.
  2. (Amended) A chimeric immunoglobulin or chimeric antigen binding fragment of Claim 1, wherein the antigen binding region is derived from a murine anti-CD4 immunoglobulin.
  3. (Amended) A chimeric immunoglobulin or chimeric antigen binding fragment of Claim 2, wherein the antigen binding region is derived from a monoclonal antibody.
  4. (Amended) A CD4-specific chimeric immunoglobulin fragment, wherein said fragment has the epitopic specificity of monoclonal antibody M-T412 and comprises an antigen binding region of non-human origin and at least a portion of a constant region of human origin.
  5. (Amended) A chimeric immunoglobulin or chimeric antigen binding fragment thereof, wherein said immunoglobulin or fragment is specific for CD4, has the epitopic specificity of monoclonal antibody M-T412, and comprises:
    - a) at least one chimeric heavy chain comprising an antigen binding region derived from the heavy chain of a non-human antibody specific for CD4 receptor linked to at least a portion of a human heavy chain constant region, the heavy chain being in association with:

b) at least one chimeric light chain comprising an antigen binding region derived from a light chain of the non-human antibody linked to at least a portion of a human light chain constant region.

6. (Amended) A chimeric immunoglobulin or chimeric antigen binding fragment of Claim 5, wherein the antigen binding region is derived from a murine antibody.

A<sup>1</sup> 7. (Amended) A chimeric immunoglobulin Fab, Fab' or F(ab')<sub>2</sub> fragment which has the epitopic specificity of monoclonal antibody M-T412 and comprises a non-human variable region of an antibody which is specific for the CD4 receptor and a human constant region.

13. (Amended) A method of therapy for an autoimmune disorder, comprising administering to a patient a therapeutically effective amount of a CD4-specific chimeric immunoglobulin or chimeric antigen binding fragment of Claim 1.

14. (Amended) The method of Claim 13, wherein the antigen binding region is derived from a murine anti-CD4 immunoglobulin.

15. (Amended) The method of Claim 13, wherein the murine anti-CD4 immunoglobulin is monoclonal antibody M-T412.

---

16. (New) The method of Claim 13, wherein a chimeric antigen binding fragment is administered.

A<sup>2</sup> 17. (New) The method of Claim 16, wherein the chimeric antigen binding fragment is an Fab fragment, Fab' fragment or F(ab')<sub>2</sub> fragment.

18. (New) A CD4-specific chimeric immunoglobulin or chimeric antigen binding fragment of Claim 1, wherein the antigen binding region of non-human origin is from monoclonal antibody M-T412.